Andrew Li, PharmD, BCOP, discusses key targeted therapy updates in the 2026 ASCO living guideline for stage IV non–small cell lung cancer and how pharmacists can help manage treatment-related toxicities and access barriers.
Andrew Li, PharmD, BCOP
Advertisement
Articles by Andrew Li, PharmD, BCOP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
Closing the Kidney Gap in Cardio-Kidney-Metabolic Care
2
Medicare's New GLP-1 Bridge Program: What Pharmacists Need to Know Before Dispensing
3
GLP-1 RAs Linked to Lower Mortality, Amputation Risk in Patients With PAD and Type 2 Diabetes
4
Pharmacists Can Help Patients Navigate GLP-1 Access, Affordability, and Long-Term Use
5